Back to Search
Start Over
Delivery of an mi R155 inhibitor by anti- CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis.
- Source :
- Clinical & Experimental Immunology; May2014, Vol. 176 Issue 2, p207-221, 15p
- Publication Year :
- 2014
-
Abstract
- MicroRNA-155 (mi R155) is required for antibody production after vaccination with attenuated Salmonella. mi R155-deficient B cells generated reduced germinal centre responses and failed to produce high-affinity immunoglobulin ( Ig)G1 antibodies. In this study, we observed up-regulation of mi R155 in the peripheral blood mononuclear cells ( PBMCs) of patients with myasthenia gravis ( MG), and mi R155 was also up-regulated in torpedo acetylcholine receptor ( T- AChR)-stimulated B cells. We used an inhibitor of mi R155 conjugated to anti- CD20 single-chain antibody to treat both the cultured B cells and the experimental autoimmune MG ( EAMG) mice. Our results demonstrated that silencing of mi R155 by its inhibitor impaired the B cell-activating factor ( BAFF)- R-related signalling pathway and reduced the translocation of nuclear factor ( NF)-κ B into the nucleus. Additionally, AChR-specific autoantibodies were reduced, which may be related to the altered amounts of marginal zone B cells and memory B cells in the spleens of EAMG mice. Our study suggests that mi R155 may be a promising target for the clinical therapy of MG. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00099104
- Volume :
- 176
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Clinical & Experimental Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 95466288
- Full Text :
- https://doi.org/10.1111/cei.12265